us fda curbs mass compounding
Limits Unsafe Copies for Prescription Weight Loss
On April 30, 2026 the FDA announced a proposal to remove semaglutide, tirzepatide and liraglutide from the 503B bulk-drug list, effectively stopping large-scale compounding of these GLP-1 agents. By forcing production to go through manufacturers or vetted specialty pharmacies, the agency aims to eliminate mislabeled or under-dosed copies that have